StockNow
Calendar
Log in
Other

Genmab (GMAB DC) Phase 3 Rina data in ovarian cancer shows PFS and OS endpoints were met

StockNow breaking-news AI analysis

Genmab reported that RAINFOL-02 met PFS and OS endpoints, with significant results in ITT and PAS populations; the announcement also notes a patient-count discrepancy and unestablished safety and efficacy.

1 stocks
GMABGenmab A/S ADS$43.36Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Politics

US Treasury Secretary Bessent posts "... the United States is no longer managing the Iranian threat. We are ending it."

U.S. Economy

US S&P Global Services PMI Flash (Oct) 57.9 vs. Exp. 58 (Prev. 58.8)

SPGIPolitics

[MARKET UPDATE] Spot gold slips below USD 4k/oz, but remains just above the USD 3986/oz low. Further, modest, pressure seen in equity futures.